Patients with BCR::ABL1 transcript levels < 1% at 6 months and MMR at 18 months showed an impact in the PFS and OS, as seen in the CML-IV study [19]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.